Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02860780
Title A Study of Prexasertib (LY2606368) in Combination With Ralimetinib in Participants With Advanced or Metastatic Cancer
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements Yes
Sponsors Eli Lilly and Company
Indications

lung non-small cell carcinoma

colon cancer

Advanced Solid Tumor

Therapies

Prexasertib + Ralimetinib

Age Groups: adult | senior
Covered Countries USA | DEU

Facility Status City State Zip Country Details
Carolinas Medical Center Charlotte North Carolina 28204 United States Details
Sarah Cannon Research Institute SCRI Nashville Tennessee 37203 United States Details
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Köln 50937 Germany Details
*Shaded cells indicate that there was no data available from clincialtrials.gov for the field